BMJ  2006;332:1177-1181 (20 May), doi:10.1136/bmj.38803.528113.55 (published 5 May 2006)

Research

Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine

¹ West Midlands Centre for Adverse Drug Reaction Reporting, City Hospital, Birmingham B18 7QH, ² Department of Clinical Pharmacology, University of Birmingham, Birmingham B15 2TH

Abstract

Objective To review the evidence for ethnic differences in susceptibility to adverse drug reactions (ADRs) to cardiovascular drugs.

Design Systematic review and meta-analysis.

Data sources We searched Medline and Embase to March 2005. Reference lists of identified articles were hand searched for further relevant articles.

Review methods Studies were eligible for inclusion if they included at least two ethnic groups and one or more ADRs. We excluded case reports and case series.

Results 564 studies contained some description of ethnicity and an ADR, and 132 of them related to cardiovascular therapies. Twenty four studies provided data for ADRs for at least two ethnic groups and were therefore eligible for inclusion. In pooled analyses the relative risk of angio-oedema from angiotensin converting enzyme (ACE) inhibitors in black compared with non-black patients was 3.0 (95% confidence interval 2.5 to 3.7); the relative risk of cough from ACE inhibitors was 2.7 (1.6 to 4.5) in East Asian compared with white patients; and the relative risk of intracranial haemorrhage with thrombolytic therapy was 1.5 (1.2 to 1.9) in black compared with non-black patients.

Conclusion Patients from different ethnic groups have different risks for important ADRs to cardiovascular drugs. Ethnic group may therefore be one determinant of harms of a given treatment in the individual patient, either because it acts as a surrogate measure of genetic make up or because cultural factors alter the risk. Data are sparse, and regulators should consider asking for better data before licensing.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Ethnic differences in risks of adverse reactions: Is personalised drug treatment better with pharmacokinetic modelling?

David S Millson
BMJ 2006 332: 1393. [Extract] [Full Text]

Ethnic differences in risks of adverse reactions: Biomedical approach is insufficient to explain ethnic differences

Sam W P Mhlongo and Acquira J Mbokazi
BMJ 2006 332: 1393. [Extract] [Full Text]

Ethnic misclassifications hamper progress in research

Charles Agyemang
BMJ 2006 332: 1335. [Extract] [Full Text]

Ethnicity can affect risk of adverse drug reactions
BMJ 2006 332: 0. [Full Text] [PDF]

Ethnicity and adverse drug reactions

Erik Eliasson
BMJ 2006 332: 1163-1164. [Extract] [Full Text] [PDF]

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

Munir Pirmohamed, Sally James, Shaun Meakin, Chris Green, Andrew K Scott, Thomas J Walley, Keith Farrar, B Kevin Park, and Alasdair M Breckenridge
BMJ 2004 329: 15-19. [Abstract] [Full Text] [PDF]

Joining the DoTS: new approach to classifying adverse drug reactions

J K Aronson and R E Ferner
BMJ 2003 327: 1222-1225. [Extract] [Full Text] [PDF]

Measuring inconsistency in meta-analyses

Julian P T Higgins, Simon G Thompson, Jonathan J Deeks, and Douglas G Altman
BMJ 2003 327: 557-560. [Extract] [Full Text] [PDF]

Meta-analysis: Principles and procedures

Matthias Egger, George Davey Smith, and Andrew N Phillips
BMJ 1997 315: 1533-1537. [Extract] [Full Text]

Is research into ethnicity and health racist, unsound, or important science?

Raj Bhopal
BMJ 1997 314: 1751. [Extract] [Full Text]

This article has been cited by other articles:

• Teo, K. K. (2009). Clinical evidence from ONTARGET: proven cardio- and vascular protection. Eur Heart J Suppl 11: F9-F15 [Abstract] [Full text]  
• Dagenais, G. R. (2009). Vascular protection: telmisartan in the ONTARGET Trial Programme. Eur Heart J Suppl 11: F47-F53 [Abstract] [Full text]  
• Davis, A. M., Vinci, L. M., Okwuosa, T. M., Chase, A. R., Huang, E. S. (2007). Cardiovascular Health Disparities: A Systematic Review of Health Care Interventions. Med Care Res Rev 64: 29S-100S [Abstract]  
• Aspinall, P. J, Jacobson, B. (2007). Why poor quality of ethnicity data should not preclude its use for identifying disparities in health and healthcare. Qual Saf Health Care 16: 176-180 [Abstract] [Full text]  
• (2006). Ethnicity Affects Reactions to Cardiovascular Drugs. JWatch General 2006: 5-5 [Full text]  
• Millson, D. S (2006). Ethnic differences in risks of adverse reactions: is personalised drug treatment better with pharmacokinetic modelling?. BMJ 332: 1393-1393 [Full text]  
• Mhlongo, S. W P, Mbokazi, A. J (2006). Ethnic differences in risks of adverse reactions: Biomedical approach is insufficient to explain ethnic differences.. BMJ 332: 1393-1393 [Full text]  
• Agyemang, C. (2006). Ethnic misclassifications hamper progress in research.. BMJ 332: 1335-1335 [Full text]  
• Eliasson, E. (2006). Ethnicity and adverse drug reactions.. BMJ 332: 1163-1164 [Full text]  

Rapid Responses:

Read all Rapid Responses

Ethnicity and adverse drug reactions: Inappropriate ethnic classifications are hampering progress in ethnicity and heath research

Charles Agyemang PhD
bmj.com, 22 May 2006 [Full text]

Biomedical approach insufficient to explain ethnic differences

Sam W. P. Mhlongo, et al.
bmj.com, 28 May 2006 [Full text]

Personalised drug treatment better by design with PK/PD?

David S Millson
bmj.com, 30 May 2006 [Full text]

Poor data, misleading message: 'ethnic differences' in adverse drug reactions

Hilda Parker, et al.
bmj.com, 27 Jun 2006 [Full text]

Online poll

Find out more on doc2doc >>